Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, will be presenting at the ThinkEquity ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

Staying at Hope Lodge gives a sense of comfort and community to cancer patients and their caregivers, Taylor said. Not only ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds ...

Bill Traverso and his family are advocating for pediatric cancer awareness after his granddaughter, Harper Thair, battled ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.